Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Moodys
McKinsey
Express Scripts
Colorcon

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Daratumumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Daratumumab: Patents, clinical trial progress, indications

Daratumumab is an investigational drug.

There have been 123 clinical trials for Daratumumab. The most recent clinical trial was a Phase 1 trial, which was initiated on January 15th 2019.

The most common disease conditions in clinical trials are Multiple Myeloma, Neoplasms, Plasma Cell, and Leukemia. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen, LP, and National Cancer Institute (NCI).

There are eight US patents protecting this investigational drug and one hundred and ninety-six international patents.

Recent Clinical Trials for Daratumumab
TitleSponsorPhase
Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple MyelomaJanssen, LPPhase 2
Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple MyelomaTakedaPhase 2
Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple MyelomaEmory UniversityPhase 2

See all Daratumumab clinical trials

Clinical Trial Summary for Daratumumab

Top disease conditions for Daratumumab
Top clinical trial sponsors for Daratumumab

See all Daratumumab clinical trials

US Patents for Daratumumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Daratumumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Daratumumab   Start Trial Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts Advenchen Pharmaceuticals, LLC (Moorpark, CA)   Start Trial
Daratumumab   Start Trial Blocking CD38 using anti-CD38 F(ab')2 to protect NK cells The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) Janssen Biotech, Inc. (Spring House, PA)   Start Trial
Daratumumab   Start Trial Treating myelomas Mayo Foundation for Medical Education and Research (Rochester, MN)   Start Trial
Daratumumab   Start Trial Mesalamine for the treatment of cancer Cipla Limited (Mumbai, IN)   Start Trial
Daratumumab   Start Trial Constructs having a SIRP-.alpha. domain or variant thereof ALX ONCOLOGY INC. (Burlingame, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Daratumumab

Drugname Country Document Number Estimated Expiration Related US Patent
Daratumumab Canada 2900764 2033-02-08   Start Trial
Daratumumab European Patent Office 2954056 2033-02-08   Start Trial
Daratumumab Hong Kong 1218930 2033-02-08   Start Trial
Daratumumab Japan 2016509014 2033-02-08   Start Trial
Daratumumab World Intellectual Property Organization (WIPO) 2014124326 2033-02-08   Start Trial
Daratumumab Australia 2016257816 2035-05-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Medtronic
Express Scripts
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.